BR112016003868A8 - Método, aparelho, mídia de armazenamento não transitório, e, programa de computador - Google Patents
Método, aparelho, mídia de armazenamento não transitório, e, programa de computadorInfo
- Publication number
- BR112016003868A8 BR112016003868A8 BR112016003868A BR112016003868A BR112016003868A8 BR 112016003868 A8 BR112016003868 A8 BR 112016003868A8 BR 112016003868 A BR112016003868 A BR 112016003868A BR 112016003868 A BR112016003868 A BR 112016003868A BR 112016003868 A8 BR112016003868 A8 BR 112016003868A8
- Authority
- BR
- Brazil
- Prior art keywords
- computer program
- perform
- trainer
- storage media
- tissue
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 6
- 238000004590 computer program Methods 0.000 title abstract 3
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 abstract 2
- 108091007960 PI3Ks Proteins 0.000 abstract 2
- 210000001124 body fluid Anatomy 0.000 abstract 2
- 239000010839 body fluid Substances 0.000 abstract 2
- 230000005754 cellular signaling Effects 0.000 abstract 2
- 230000037361 pathway Effects 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000001052 transient effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C99/00—Subject matter not provided for in other groups of this subclass
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Theoretical Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Evolutionary Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Medical Informatics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Computing Systems (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Algebra (AREA)
- General Physics & Mathematics (AREA)
- Mathematical Analysis (AREA)
- Mathematical Optimization (AREA)
- Mathematical Physics (AREA)
- Pure & Applied Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
MÉTODO, APARELHO, MÍDIA DE ARMAZENAMENTO NÃO TRANSITÓRIO, E, PROGRAMA DE COMPUTADOR. A presente invenção refere-se a um método que compreende inferir a atividade de uma via de sinalização celular PI3K em um tecido e/ou em células e/ou em um fluido corpóreo de um paciente, com base ao menos nos níveis de expressão de um ou mais genes-alvo da via de sinalização celular PI3K medidos em uma amostra extraída do tecido e/ou das células e/ou do fluido corpóreo do paciente. A presente invenção refere-se, adicionalmente, a um aparelho que compreende um processador digital configurado para executar esse tipo de método, a uma mídia de armazenamento não transitório que armazena instruções que são executáveis por um dispositivo de processamento digital para executar esse tipo de método, e a um programa de computador que compreende meios de código de programa para fazer com que um dispositivo de processamento digital execute esse tipo de método.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14150145 | 2014-01-03 | ||
| PCT/EP2014/079468 WO2015101635A1 (en) | 2014-01-03 | 2014-12-30 | Assessment of the pi3k cellular signaling pathway activity using mathematical modelling of target gene expression. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112016003868A2 BR112016003868A2 (pt) | 2017-12-05 |
| BR112016003868A8 true BR112016003868A8 (pt) | 2022-11-08 |
Family
ID=49920140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016003868A BR112016003868A8 (pt) | 2014-01-03 | 2014-12-30 | Método, aparelho, mídia de armazenamento não transitório, e, programa de computador |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11261495B2 (pt) |
| EP (1) | EP3013986B1 (pt) |
| JP (1) | JP6077178B2 (pt) |
| CN (2) | CN112795650A (pt) |
| AU (1) | AU2014375206B2 (pt) |
| BR (1) | BR112016003868A8 (pt) |
| CA (1) | CA2923092C (pt) |
| DK (1) | DK3013986T3 (pt) |
| ES (1) | ES2613521T3 (pt) |
| WO (1) | WO2015101635A1 (pt) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015334841B2 (en) | 2014-10-24 | 2022-02-03 | Koninklijke Philips N.V. | Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities |
| CA2965408C (en) | 2014-10-24 | 2023-10-24 | Koninklijke Philips N.V. | Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities |
| US10016159B2 (en) | 2014-10-24 | 2018-07-10 | Koninklijke Philips N.V. | Determination of TGF-β pathway activity using unique combination of target genes |
| BR112018002848A2 (pt) | 2015-08-14 | 2018-11-06 | Koninklijke Philips Nv | método, aparelho, mídia de armazenamento não transitório, programa de computador, kit para medir níveis de expressão de seis ou mais genes-alvo da via de sinalização celular |
| RU2019100441A (ru) * | 2016-06-13 | 2020-07-14 | Конинклейке Филипс Н.В. | Способ логического вывода об активности транскрипционного фактора пути сигнальной трансдукции у субъекта |
| CN110382521B (zh) * | 2016-11-25 | 2024-07-05 | 皇家飞利浦有限公司 | 从氧化应激区分肿瘤抑制性foxo活性的方法 |
| EP3431582A1 (en) | 2017-07-18 | 2019-01-23 | Koninklijke Philips N.V. | Cell culturing materials |
| EP3462348A1 (en) | 2017-09-28 | 2019-04-03 | Koninklijke Philips N.V. | Bayesian inference |
| CA3077501A1 (en) * | 2017-10-02 | 2019-04-11 | Koninklijke Philips N.V. | Determining functional status of immune cells types and immune response |
| EP3461915A1 (en) * | 2017-10-02 | 2019-04-03 | Koninklijke Philips N.V. | Assessment of jak-stat1/2 cellular signaling pathway activity using mathematical modelling of target gene expression |
| EP3502279A1 (en) * | 2017-12-20 | 2019-06-26 | Koninklijke Philips N.V. | Assessment of mapk-ap 1 cellular signaling pathway activity using mathematical modelling of target gene expression |
| JP7406213B2 (ja) * | 2018-01-24 | 2023-12-27 | トーマス・ジェファーソン・ユニバーシティ | バイオ拡散チャンバおよびその製造方法 |
| EP3812474A1 (en) | 2019-10-22 | 2021-04-28 | Koninklijke Philips N.V. | Methods of prognosis in high-grade serous ovarian cancer |
| JP7386897B2 (ja) * | 2019-05-03 | 2023-11-27 | コーニンクレッカ フィリップス エヌ ヴェ | 高悪性度漿液性卵巣癌における予後予測の方法 |
| EP3739588A1 (en) | 2019-05-13 | 2020-11-18 | Koninklijke Philips N.V. | Assessment of multiple signaling pathway activity score in airway epithelial cells to predict airway epithelial abnormality and airway cancer risk |
| EP3882363A1 (en) | 2020-03-17 | 2021-09-22 | Koninklijke Philips N.V. | Prognostic pathways for high risk sepsis patients |
| EP3978628A1 (en) | 2020-10-01 | 2022-04-06 | Koninklijke Philips N.V. | Prognostic pathways for viral infections |
| WO2021209567A1 (en) | 2020-04-16 | 2021-10-21 | Koninklijke Philips N.V. | Prognostic pathways for viral infections |
| EP3940704A1 (en) | 2020-07-14 | 2022-01-19 | Koninklijke Philips N.V. | Method for determining the differentiation state of a stem cell |
| EP3960875A1 (en) | 2020-08-28 | 2022-03-02 | Koninklijke Philips N.V. | Pcr method and kit for determining pathway activity |
| EP3965119A1 (en) | 2020-09-04 | 2022-03-09 | Koninklijke Philips N.V. | Methods for estimating heterogeneity of a tumour based on values for two or more genome mutation and/or gene expression related parameter, as well as corresponding devices |
| EP3974540A1 (en) | 2020-09-25 | 2022-03-30 | Koninklijke Philips N.V. | Method for predicting immunotherapy resistance |
| EP4015651A1 (en) | 2020-12-17 | 2022-06-22 | Koninklijke Philips N.V. | Treatment prediction and effectiveness of anti-tnf alpha treatment in ibd patients |
| EP4039825A1 (en) | 2021-02-09 | 2022-08-10 | Koninklijke Philips N.V. | Comparison and standardization of cell and tissue culture |
| WO2022189530A1 (en) | 2021-03-11 | 2022-09-15 | Koninklijke Philips N.V. | Prognostic pathways for high risk sepsis patients |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1592791A2 (en) * | 2003-02-10 | 2005-11-09 | National Institute of Advanced Industrial Science and Technology | Regulation of gene expression by dna interference |
| RU2010111116A (ru) * | 2007-08-24 | 2011-09-27 | Онкотерапи Сайенс, Инк. (Jp) | Pkib и naaladl2 в качестве генов-мишеней в терапии и диагностике рака предстательной железы |
| KR20110052627A (ko) * | 2008-07-16 | 2011-05-18 | 다나-파버 캔서 인스티튜트 인크. | 전립선암과 관련된 시그너처 및 ｐｃ결정인자 및 그의 사용 방법 |
| MX2012011887A (es) * | 2010-04-16 | 2012-11-30 | Genentech Inc | Foxo 3a como biomarcador predictivo para la eficacia del inhibidor de la via de quinasa pi3k/akt. |
| EP2549399A1 (en) | 2011-07-19 | 2013-01-23 | Koninklijke Philips Electronics N.V. | Assessment of Wnt pathway activity using probabilistic modeling of target gene expression |
| JP6449779B2 (ja) | 2012-12-26 | 2019-01-09 | コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． | 目的遺伝子発現の線形結合を用いた細胞信号伝達経路活性の評価 |
| US11309059B2 (en) | 2013-04-26 | 2022-04-19 | Koninklijke Philips N.V. | Medical prognosis and prediction of treatment response using multiple cellular signalling pathway activities |
| EP3461916A1 (en) * | 2017-10-02 | 2019-04-03 | Koninklijke Philips N.V. | Assessment of jak-stat3 cellular signaling pathway activity using mathematical modelling of target gene expression |
-
2014
- 2014-12-30 CA CA2923092A patent/CA2923092C/en active Active
- 2014-12-30 CN CN202110045252.6A patent/CN112795650A/zh active Pending
- 2014-12-30 BR BR112016003868A patent/BR112016003868A8/pt not_active Application Discontinuation
- 2014-12-30 US US15/023,820 patent/US11261495B2/en active Active
- 2014-12-30 AU AU2014375206A patent/AU2014375206B2/en active Active
- 2014-12-30 JP JP2016515946A patent/JP6077178B2/ja active Active
- 2014-12-30 DK DK14824498.1T patent/DK3013986T3/en active
- 2014-12-30 ES ES14824498.1T patent/ES2613521T3/es active Active
- 2014-12-30 CN CN201480048682.1A patent/CN105492630A/zh active Pending
- 2014-12-30 WO PCT/EP2014/079468 patent/WO2015101635A1/en active Application Filing
- 2014-12-30 EP EP14824498.1A patent/EP3013986B1/en active Active
-
2022
- 2022-01-17 US US17/577,078 patent/US20220259666A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP6077178B2 (ja) | 2017-02-08 |
| US11261495B2 (en) | 2022-03-01 |
| AU2014375206B2 (en) | 2021-09-30 |
| BR112016003868A2 (pt) | 2017-12-05 |
| ES2613521T3 (es) | 2017-05-24 |
| EP3013986B1 (en) | 2016-11-16 |
| CN112795650A (zh) | 2021-05-14 |
| US20220259666A1 (en) | 2022-08-18 |
| JP2016536976A (ja) | 2016-12-01 |
| WO2015101635A1 (en) | 2015-07-09 |
| AU2014375206A1 (en) | 2016-03-03 |
| CN105492630A (zh) | 2016-04-13 |
| US20160298196A1 (en) | 2016-10-13 |
| CA2923092A1 (en) | 2015-07-09 |
| CA2923092C (en) | 2019-12-17 |
| EP3013986A1 (en) | 2016-05-04 |
| DK3013986T3 (en) | 2017-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112016003868A8 (pt) | Método, aparelho, mídia de armazenamento não transitório, e, programa de computador | |
| BR112015015131A2 (pt) | método, aparelho, mídia de armazenamento não transitório, programa de computador, e produto | |
| BR112018002848A2 (pt) | método, aparelho, mídia de armazenamento não transitório, programa de computador, kit para medir níveis de expressão de seis ou mais genes-alvo da via de sinalização celular | |
| BR112014000965B8 (pt) | Método, aparelho e meio de armazenamento não transitório | |
| BR112018008357A2 (pt) | mutações de ponto em câncer resistente a inibidor de trk e métodos relacionados às mesmas | |
| BR112019022538A8 (pt) | Técnicas para pareamento comportamental em um sistema de centro de contato | |
| BR112017026709A2 (pt) | tratamento e diagnóstico de câncer | |
| BR112017025045A2 (pt) | plx-8394 ou plx-7904 para uso no tratamento de doenças relacionadas a braf-v600 | |
| GB2552267A (en) | Detection and treatment of disease exhibiting disease cell heterogeneity and systems and methods for communicating test results | |
| BR112016016658A2 (pt) | proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão | |
| BR112019010553A2 (pt) | método para inferir a atividade de uma via de sinalização celular pi3k em um indivíduo e programa de computador | |
| BR112016020897A2 (pt) | ?determinação da agressividade de câncer, prognóstico e capacidade de reação a tratamento? | |
| BR112014026648A8 (pt) | método implementado por um dispositivo de computação e aparelho para determinar uma porção futura de um programa de mídia | |
| WO2017116817A3 (en) | Testing of medicinal drugs and drug combinations | |
| CY1123793T1 (el) | Γονιδιακη θεραπεια rpgr για μελαγχρωστικη αμφιβληστροειδοπαθεια | |
| WO2014124339A3 (en) | Use of translational profiling to identify target molecules for therapeutic treatment | |
| BR112018003238A2 (pt) | seleção de pacientes para terapia de combinação | |
| EA201790211A1 (ru) | Способ прогнозирования результата лечения афлиберцептом пациента, предположительно страдающего от рака | |
| BR112017014361A2 (pt) | métodos para aperfeiçoamento de terapia celular | |
| BR112015030526A2 (pt) | detecção de aorta automatizada em um volume de tca | |
| BR112016024143A2 (pt) | tratamento de câncer | |
| BR112015017903A2 (pt) | vacina de subunidade de mycobacterium avium subsp. paratuberculosis única ou de múltiplos estágios | |
| MX2020006388A (es) | Biomarcadores para el diagnostico y pronostico de trastornos ectaticos de la cornea. | |
| MX2017006959A (es) | Metodos para establecer un regimen de dosificacion de vedolizumab para tratar pacientes con enfermedad del intestino irritable. | |
| BR112017008805A2 (pt) | tratamento de córnea usando laminina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: INNOSIGN B.V. (NL) |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |